Overview

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
Phase:
Phase 2
Details
Lead Sponsor:
Eugene F Yen, MD
Treatments:
Rifaximin